Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578553 | 0.85 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL10985744 | 0.83 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL7018973 | 0.83 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL10989428 | 0.83 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL10989407 | 0.83 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL22342660 | 0.82 | ALDH1A1 (0.51) | KDM4ETSHRLMNAL3MBTL1MAPT | |
| SCHEMBL1888194 | 0.81 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL1888197 | 0.81 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC6ERN1 | |
| SCHEMBL2226671 | 0.80 | NPSR1 (0.53) | ERN1KDM4ETSHRLMNAL3MBTL1 | |
| SCHEMBL8839266 | 0.80 | CYP3A4 (0.49) | HDAC3HDAC4HDAC1HDAC6ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390668-A | Compound with ketoxime ether structure and application thereof | 复旦大学 | 2025-02-07 | — | — | CN | disclosed |
| EP-2890691-B1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9573958-B2 | Benzimidazole derivatives as ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-3114124-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2015134210-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2890691-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | Principia Biopharma Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014036016-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| US-4931458-A | Heterocyclic rodenticidal compounds, compositions containing the compounds, and methods of use | HOFFMANN-LA ROCHE INC. (US) | 1990-06-05 | — | — | US | disclosed |
| US-4816476-A | BENZO(B)THIENYL GROUP OR BENZOFURAN SUBSTITUTED GROUPS | HOFFMANN-LA ROCHE INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4659735-A | Benzofuranyl (thienyl) propenyl derivatives useful as rodenticides | HOFFMANN-LA ROCHE INC. (US) | 1987-04-21 | — | — | US | disclosed |
| US-4535086-A | RODENTICIDES | HOFFMANN-LA ROCHE INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | BMX, ITK, BLK | HDAC3 1471/4885HDAC4 567/4885HDAC1 1406/4885 |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | ITK, BLK, LMTK2 | HDAC3 1032/4885HDAC4 650/4885HDAC1 644/4885 |
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | HDAC3 203/4885HDAC4 396/4885HDAC1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.